Cellectis S.A. ADR (CLLS)

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

By Luke Lango, InvestorPlace Senior Investment Analyst Jul 1, 2021

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.

7 CRISPR Stocks for the Future of Medicine

By Luke Lango, InvestorPlace Senior Investment Analyst Jan 15, 2021

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.

Cellectis draws down second tranche under EIB credit facility (NASDAQ:CLLS)

From Seeking Alpha Jan 16, 2024

Cellectis (CLLS) said it has drawn down a second tranche of EUR 15M under a credit facility agreement with the European Investment Bank, or EIB. Read more here.

Cellectis stock jumps on execution of $140M additional investment with AstraZeneca

From Seeking Alpha Nov 15, 2023

Cellectis shares surge after binding agreement with AstraZeneca for $140M equity investment to drive cell and gene therapy development.

There's a Lot of Upside For Emerging Gene-Editing Companies

From MarketBeat Feb 21, 2023

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

Cellectis stock plunges ~17% after hours on $22M ADS offering (NASDAQ:CLLS)

From Seeking Alpha Feb 2, 2023

Cellectis (CLLS) on Thursday launched a global offering of USD22 million of its American Depositary Shares.

CLLS stock rises as terms of Cytovia licensing deal change (NASDAQ:CLLS)

From Seeking Alpha Jan 23, 2023

Cellectis S.A. (CLLS) added ~9% pre-market Monday after announcing changes to the certain financial terms of its partnership with Cytovia Therapeutics. Read the full story here.

Robert W. Baird Keeps Their Buy Rating on Cellectis SA (CLLS)

From TipRanks Dec 2, 2022

In a report released on November 30, Jack Allen from Robert W. Baird maintained a Buy rating on Cellectis SA (CLLS – Research Report), with a price...

Cellectis S.A. ADR (CLLS)

CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Why Is Cellectis (CLLS) Stock Up 175% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Cellectis S.A. ADR (CLLS)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

CLLS Stock Predictions, Articles, and Cellectis S.A. ADR News

Subscriber Sign in